CY1112288T1 - Θεραπεια του καρκινου με αντισωματα κατα της il-1a - Google Patents

Θεραπεια του καρκινου με αντισωματα κατα της il-1a

Info

Publication number
CY1112288T1
CY1112288T1 CY20121100014T CY121100014T CY1112288T1 CY 1112288 T1 CY1112288 T1 CY 1112288T1 CY 20121100014 T CY20121100014 T CY 20121100014T CY 121100014 T CY121100014 T CY 121100014T CY 1112288 T1 CY1112288 T1 CY 1112288T1
Authority
CY
Cyprus
Prior art keywords
cancer treatment
antibodies against
immunization
antibody
patient
Prior art date
Application number
CY20121100014T
Other languages
English (en)
Inventor
John Simard
Original Assignee
Xbiotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech, Inc. filed Critical Xbiotech, Inc.
Publication of CY1112288T1 publication Critical patent/CY1112288T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Θεραπεία ασθενούς με αντίσωμα κατά της ΙL-1α ή ανοσοποίηση κατά της ΙL-1α ως θεραπεία κατά του καρκίνου.
CY20121100014T 2006-05-22 2012-01-05 Θεραπεια του καρκινου με αντισωματα κατα της il-1a CY1112288T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80216606P 2006-05-22 2006-05-22
EP07734628A EP2109623B1 (en) 2006-05-22 2007-05-22 Treatment of cancer with anti-il-1 antibodies

Publications (1)

Publication Number Publication Date
CY1112288T1 true CY1112288T1 (el) 2015-12-09

Family

ID=38670649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100014T CY1112288T1 (el) 2006-05-22 2012-01-05 Θεραπεια του καρκινου με αντισωματα κατα της il-1a

Country Status (15)

Country Link
US (3) US20100040574A1 (el)
EP (1) EP2109623B1 (el)
JP (3) JP2009537628A (el)
CN (3) CN101472948A (el)
AT (1) ATE528319T1 (el)
AU (1) AU2007252990B2 (el)
CA (1) CA2652870C (el)
CY (1) CY1112288T1 (el)
DK (1) DK2109623T3 (el)
ES (1) ES2374845T3 (el)
HK (1) HK1243943A1 (el)
PL (1) PL2109623T3 (el)
PT (1) PT2109623E (el)
SI (1) SI2109623T1 (el)
WO (1) WO2007135546A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915620B1 (en) 2005-08-02 2010-06-02 Xbiotech Inc DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1alpha AUTOANTIBODIES
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US8034337B2 (en) 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
AU2009291536B2 (en) 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
TWI615405B (zh) 2010-05-14 2018-02-21 艾伯維有限公司 Ｉｌ-１結合蛋白
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
AU2015271978B2 (en) * 2010-08-23 2017-10-26 Xbiotech Inc. Treatment for neoplastic diseases
RU2679119C2 (ru) * 2010-08-23 2019-02-06 ИксБиотеч, Инк. Лечение неопластических заболеваний
AU2015201228B2 (en) * 2010-08-23 2016-02-11 Xbiotech Inc. Treatment for neoplastic diseases
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN103906536A (zh) 2011-09-23 2014-07-02 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2018220862A1 (en) 2017-02-16 2019-08-29 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JPH06339394A (ja) * 1986-11-13 1994-12-13 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−１αに対するモノクローナル抗体
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
JPH02157231A (ja) * 1988-12-07 1990-06-18 Bio Kagaku Kenkyusho:Kk 細胞増殖抑制剤
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DE69327659T2 (de) * 1992-10-14 2000-09-21 Nycomed Imaging As Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2004022718A2 (en) * 2002-09-06 2004-03-18 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) * 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
EP1915620B1 (en) * 2005-08-02 2010-06-02 Xbiotech Inc DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1alpha AUTOANTIBODIES
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090191149A1 (en) * 2006-05-15 2009-07-30 Xbiotech Inc. IL-1alpha IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
KR101328756B1 (ko) * 2006-05-30 2013-11-18 제넨테크, 인크. 항체 및 면역접합체 및 이들의 용도
US8034337B2 (en) * 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
AU2009291536B2 (en) * 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
ES2374845T3 (es) 2012-02-22
SI2109623T1 (sl) 2012-05-31
CN102580086A (zh) 2012-07-18
JP2009537628A (ja) 2009-10-29
WO2007135546A2 (en) 2007-11-29
US20100040574A1 (en) 2010-02-18
PL2109623T3 (pl) 2012-03-30
US20190169287A1 (en) 2019-06-06
JP2015166401A (ja) 2015-09-24
JP2013126990A (ja) 2013-06-27
AU2007252990B2 (en) 2011-10-27
EP2109623A2 (en) 2009-10-21
DK2109623T3 (da) 2012-01-30
CN107158376A (zh) 2017-09-15
ATE528319T1 (de) 2011-10-15
WO2007135546A3 (en) 2008-02-07
HK1243943A1 (zh) 2018-07-27
US20160159899A1 (en) 2016-06-09
AU2007252990A1 (en) 2007-11-29
JP5992843B2 (ja) 2016-09-14
EP2109623B1 (en) 2011-10-12
CN101472948A (zh) 2009-07-01
JP6359492B2 (ja) 2018-07-18
CA2652870C (en) 2014-12-02
CA2652870A1 (en) 2007-11-29
PT2109623E (pt) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
NL301089I2 (nl) imlifidase
CY1120412T1 (el) Μορια εξανθρωπισμενου αντισωματος ειδικα για il-31
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
NO20084546L (no) Diagnostikk og behandlinger for tumorer
TR201821029T4 (tr) Geliştirilmiş antı-IL-23p19 antikorları.
BRPI0518104A (pt) métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
DK2056874T3 (da) Tumorterapi med et anti-vegf-antistof
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
DK3002298T3 (da) Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
BRPI0921805A2 (pt) anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CY1124281T1 (el) Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες